Peptide drug development has made great progress in the last decade thanks to new
production, modification, and analytic technologies. Peptides have been produced and …

Alteplase is currently the only approved thrombolytic agent for treatment of acute ischaemic
stroke, but interest is burgeoning in the development of new thrombolytic agents for systemic …

Ischemic stroke caused by arterial occlusion is the most common type of stroke, which is
among the most frequent causes of disability and death worldwide. Current treatment …

Since the introduction of insulin almost a century ago, more than 80 peptide drugs have
reached the market for a wide range of diseases, including diabetes, cancer, osteoporosis …

Stroke is the leading cause of disability and thesecond leading cause of death worldwide.
With the global population aged 65 and over growing faster than all other age groups, the …

Stroke is the second leading cause of death worldwide and a leading cause of disability.
Most strokes are caused by occlusion of a major cerebral artery, and substantial advances …

Ischemic stroke caused by intracranial vascular occlusion has become increasingly
prevalent with considerable mortality and disability, which gravely burdens the global …

Excitotoxicity is classically defined as the neuronal damage caused by the excessive
release of glutamate, and subsequent activation of excitatory plasma membrane receptors …

Ischemic stroke is the main cause of death and the most common cause of acquired physical
disability worldwide. Recent demographic changes increase the relevance of stroke and its …

The treatment of acute ischemic stroke continues to advance. The mainstay of treatment
remains intravenous thrombolysis with alteplase. Recent studies demonstrated that later …